DE69521924T2 - Pharmazeutische Darreichungsformen mit verzögerter Wirkstoffabgabe enthaltend Alfuzosinhydrochlorid - Google Patents

Pharmazeutische Darreichungsformen mit verzögerter Wirkstoffabgabe enthaltend Alfuzosinhydrochlorid

Info

Publication number
DE69521924T2
DE69521924T2 DE69521924T DE69521924T DE69521924T2 DE 69521924 T2 DE69521924 T2 DE 69521924T2 DE 69521924 T DE69521924 T DE 69521924T DE 69521924 T DE69521924 T DE 69521924T DE 69521924 T2 DE69521924 T2 DE 69521924T2
Authority
DE
Germany
Prior art keywords
dosage forms
drug delivery
pharmaceutical dosage
alfuzosin hydrochloride
delayed drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69521924T
Other languages
English (en)
Other versions
DE69521924D1 (de
Inventor
Veronique Andrieu
Jean Montel
Alexander Wick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of DE69521924D1 publication Critical patent/DE69521924D1/de
Application granted granted Critical
Publication of DE69521924T2 publication Critical patent/DE69521924T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cephalosporin Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69521924T 1994-03-21 1995-03-13 Pharmazeutische Darreichungsformen mit verzögerter Wirkstoffabgabe enthaltend Alfuzosinhydrochlorid Expired - Lifetime DE69521924T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9403257A FR2717388B1 (fr) 1994-03-21 1994-03-21 Formes galéniques à libération prolongée du chlorhydrate d'alfuzosine.

Publications (2)

Publication Number Publication Date
DE69521924D1 DE69521924D1 (de) 2001-09-06
DE69521924T2 true DE69521924T2 (de) 2002-04-11

Family

ID=9461234

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69521924T Expired - Lifetime DE69521924T2 (de) 1994-03-21 1995-03-13 Pharmazeutische Darreichungsformen mit verzögerter Wirkstoffabgabe enthaltend Alfuzosinhydrochlorid

Country Status (19)

Country Link
US (1) US5589190A (de)
EP (1) EP0673650B1 (de)
JP (1) JPH07258085A (de)
KR (1) KR950031052A (de)
CN (1) CN1116524A (de)
AT (1) ATE203672T1 (de)
AU (1) AU681236B2 (de)
CA (1) CA2144917A1 (de)
CZ (1) CZ70495A3 (de)
DE (1) DE69521924T2 (de)
FI (1) FI951300A (de)
FR (1) FR2717388B1 (de)
HU (1) HUT72635A (de)
IL (1) IL113053A (de)
NO (1) NO307813B1 (de)
NZ (1) NZ270748A (de)
PL (1) PL307773A1 (de)
SK (1) SK36595A3 (de)
ZA (1) ZA952290B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177430B1 (en) 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
IL120302A0 (en) * 1996-03-27 1997-06-10 Pfizer Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
FR2752737B1 (fr) * 1996-08-29 1998-10-02 Synthelabo Comprime a liberation controlee de chlorhydrate d'alfuzosine
CZ295066B6 (cs) * 1996-08-29 2005-05-18 Sanofi-Aventis Tableta s řízeným uvolňováním alfuzosinhydrochloridu a farmaceutická kompozice, která ji obsahuje
US20040258750A1 (en) * 1999-06-28 2004-12-23 Gerard Alaux Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
EP1064938A1 (de) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmazeutische Dosierungsformen zur kontrollierte Wirkstoffabgabe mit mindenstens ein pulsierendem Zeitverlauf
US20020054903A1 (en) * 1999-10-19 2002-05-09 Joseph Tyler Direct compression polymer tablet core
CN1720026A (zh) * 2002-10-22 2006-01-11 兰贝克赛实验室有限公司 含有阿夫唑嗪的缓释组合物
CN100372538C (zh) * 2004-08-30 2008-03-05 鲁南制药集团股份有限公司 盐酸阿夫唑嗪分散片
US20060062846A1 (en) * 2004-09-17 2006-03-23 Cimex Pharma Ag Alfuzosin tablets and synthesis
US20060062845A1 (en) * 2004-09-17 2006-03-23 Cimex Pharma Ag Alfuzosin tablets and synthesis
KR20070021806A (ko) * 2005-08-19 2007-02-23 (주)아모레퍼시픽 α1-수용체 차단제의 서방형 펠렛제제 및 이의 제조 방법
US8206742B2 (en) * 2006-01-12 2012-06-26 Wockhardt Ltd. Sustained release compositions of alfuzosin
US20070292505A1 (en) * 2006-06-15 2007-12-20 Abrika Pharmaceuticals, Inc. Controlled release alfuzosin hydrochloride formulation
US20080095844A1 (en) * 2006-10-23 2008-04-24 Rajhans Sujay Kamalakar Sustained release pharmaceutical compositions of alfuzosin and process for preparation thereof
US20080138412A1 (en) * 2006-12-06 2008-06-12 Fu-Yung Lin Sustained release alfuzosin hydrochl formulation and method for their production
US20100092556A1 (en) * 2006-12-11 2010-04-15 Kristin Arnold Alfuzosin formulations, methods of making, and methods of use
WO2008102235A1 (en) * 2007-02-20 2008-08-28 Aurobindo Pharma Limited Controlled release formulations of alfuzosin
WO2010083360A2 (en) * 2009-01-16 2010-07-22 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
WO2010099508A1 (en) 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2421888A1 (fr) * 1978-02-06 1979-11-02 Synthelabo Amides d'alkylene-diamines et leur application en therapeutique
US4716041A (en) * 1984-02-10 1987-12-29 A/S Alfred Benzon Diffusion coated multiple-units dosage form
DK62184D0 (da) * 1984-02-10 1984-02-10 Benzon As Alfred Diffusionsovertrukket polydepotpraeparat
US4925837A (en) * 1984-09-14 1990-05-15 Synthelabo Pharmaceutical compositions
FR2582513B1 (fr) * 1985-05-28 1988-08-05 Synthelabo Compositions pharmaceutiques contenant de l'alfuzosine
US5472710A (en) * 1988-04-16 1995-12-05 Schwarz Pharma Ag Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture
US5268182A (en) * 1988-06-24 1993-12-07 Abbott Laboratories Sustained-release drug dosage units of terazosin
US5169642A (en) * 1988-06-24 1992-12-08 Abbott Laboratories Sustained-release drug dosage units
US5330766A (en) * 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
US5175003A (en) * 1990-04-06 1992-12-29 Biosytes Usa, Inc. Dual mechanism controlled release system for drug dosage forms
JP3286315B2 (ja) * 1990-06-20 2002-05-27 アドバンスト ポリマー システムズ，インコーポレイティド 可溶性活性物質の調節された放出のための組成物及び方法
IE61651B1 (en) * 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release

Also Published As

Publication number Publication date
NO951055D0 (no) 1995-03-20
SK36595A3 (en) 1995-11-08
FR2717388B1 (fr) 1996-11-22
IL113053A0 (en) 1995-06-29
FI951300A0 (fi) 1995-03-20
FR2717388A1 (fr) 1995-09-22
CA2144917A1 (fr) 1995-09-22
CZ70495A3 (en) 1995-10-18
HUT72635A (en) 1996-05-28
ATE203672T1 (de) 2001-08-15
NO951055L (no) 1995-09-22
ZA952290B (en) 1996-01-24
NZ270748A (en) 1995-12-21
AU681236B2 (en) 1997-08-21
DE69521924D1 (de) 2001-09-06
EP0673650B1 (de) 2001-08-01
IL113053A (en) 1999-12-22
JPH07258085A (ja) 1995-10-09
NO307813B1 (no) 2000-06-05
CN1116524A (zh) 1996-02-14
KR950031052A (ko) 1995-12-18
US5589190A (en) 1996-12-31
PL307773A1 (en) 1995-10-02
EP0673650A1 (de) 1995-09-27
FI951300A (fi) 1995-09-22
HU9500818D0 (en) 1995-05-29
AU1495595A (en) 1995-09-28

Similar Documents

Publication Publication Date Title
DE69521924T2 (de) Pharmazeutische Darreichungsformen mit verzögerter Wirkstoffabgabe enthaltend Alfuzosinhydrochlorid
GR1002564B (el) Στερεα απο του στοματος χορηγουμενη φαρμακευτικη μορφη δοσιμετρησεως προγραμματισμενου ρυθμου απελευθερωσεως.
NO930604D0 (no) Doseringsform for medikamentavgivelse med tidsvarierende moenster
DE69206345T2 (de) Arzneimittel zur intranasalen Verabreichung, die Ketorolac R enthalten.
DE3778781D1 (de) Antiphlogistika enthaltende pharmazeutische formulierungen mit gesteuerter freigabe.
ES2034617T3 (es) Revestimiento de emulsion acuosa para una forma de dosificacion farmaceutica.
DE69832816D1 (de) Orale pharmazeutische dosierungsform mit verlängerter wirkstofffreisetzung
NZ509028A (en) Stable extended release oral dosage composition comprising a pseudoephedrine-containing core, the core being uniformly covered with a desloratadine-containing film
DE69940673D1 (de) Orales system zur verabreichung von gepulsten dosen eines arzneistoffs
DK156289A (da) Farmaceutisk praeparat indrettet til kontrolleret afgivelse af aktiv bestanddel
FI906344A (fi) Kontrollerat frigoerande farmaceutiskt preparat.
WO1999012527A3 (en) Dosage form comprising means for changing drug delivery shape
DE60226012D1 (de) Geschmacksmaskierte pharmazeutische formulierungen
DE68909772D1 (de) Diclofenac-Natrium-Arzneizubereitung mit verlängerter Wirkstoffabgabe.
ITMI913170A1 (it) Composizione farmaceutica per uso oftalmico contenente un antiinfiammatorio non steroideo ed un decongestionante come principi attivi
ATE292453T1 (de) Antivirale arznei
DE60142305D1 (de) Pharmazeutische zubereitung enthaltend n-ä2-(1,6,7,8-tetrahydro-2h-indenoä5,4 büfuran-8-yl)ethylüpropionamid ummantelt mit einer copolyvidon-enthaltenden, polyäthylenglykolfreien umhüllung
RS50298B (sr) Direktno kompresibilna matrica za kontrolisano oslobađanje pojedinačnih dnevnih doza klaritromicina
ATE304844T1 (de) Entzündungshemmende pharmazeutische formulierungen
FR2796287B1 (fr) Dispositif d'administration de medicament
DK0615439T3 (da) Iburprofenholdigt retard-lægemiddel og dets anvendelse

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-AVENTIS, PARIS, FR

8364 No opposition during term of opposition